A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells

Drug Delivery and Translational Research

Volumn 2, Issue 2, 2012, Pages 95-105

  Prasad, Preethy ^a   Cheng, Ji ^a   Shuhendler, Adam ^a   Rauth, Andrew M ^b   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Breast cancer; Doxorubicin mitomycin C; Multidrug resistance; PLN nanoparticles

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; DRUG CARRIER; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; POLYMER LIPID HYBRID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 84864752337     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0051-1     Document Type: Article

References (58)

1. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature. 2007; 446: 749-57.
2. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992; 8: 67-113.
3. Wong HL, Wu XY, Bendayan R. Multidrug resistance in solid tumors and its reversal. In: Lu Y, Mahato RI, editors. Pharmaceutical perspectives of cancer therapeutics. New York: Springer; 2007. p. 121-48.
4. Tannock IF. Tumor physiology and drug resistance. Cancer Metastasis Rev. 2001; 20: 123-32.
5. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003; 55: 3-29.
6. Gottesman MM. Mechanisms of cancer drug resistance. Ann Rev Med. 2002; 53: 615-27.
7. Mohamed I, Skeel RT. Carcinoma of breast. In: Skeel RT, editor. Handbook of cancer chemotherapy. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 269-93.
8. Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem. 1989; 58: 137-71.
9. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene. 2003; 22: 7537-52.
10. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv. 2004; 1: 27-42.
11. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003; 22: 7340-58.
12. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP dependent transporters. Natl Rev Cancer. 2003; 2: 48-58.
13. Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology. 2008; 81: 275-300.
14. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000; 11: 265-83.
15. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev. 1990; 42(3): 155-99.
16. Lugo MR, Sharom FJ. Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence of stimulating binding of both drugs. Biochem. 2005; 44: 14020-9.
17. Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta. 1999; 1461: 347-57.
18. Akan I, Akan S, Akca H, Savas B, Ozben T. Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylecysteine and buthionine sulfoximine. Cancer Cell Int. 2005; 5: 22.
19. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry. 2000; 65: 95-106.
20. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998; 95: 15665-700.
21. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein. Mol Cancer Ther. 2002; 1: 427-34.
22. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007; 26(1): 39-57.
23. Ferrero JM, Etienne MC, Formento JL, Francoual M, Rostango P, Peyrottes I, et al. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. Br J Cancer. 2000; 82(1): 171-7.
24. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, et al. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res. 2001; 92(4): 452-8.
25. Chintamani, Singh JP, Mittal MK, Saxena S, Bansal S, Bhatia A, et al. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study. World J Surg Oncol. 2005; 14(3): 61.
26. Ito K, Fujimori M, Nakata S, Hama Y, Shingu K, Kobayashi S, et al. Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncol Res. 1998; 10(2): 99-109.
27. Holen I, Wind NS (2011) Multidrug resistance in breast cancer: from in vitro models to clinical studies. J Breast Cancer 2011 (Article ID 967419): 12. doi: 10. 4061/2011/967419.
28. McHugh K, Callaghan R. Clinical trials on MDR reversal agents. In: Colabufo NA, editor. Multidrug resistance: biological and pharmaceutical advance in antitumour treatment. India: Research Signpost Kerala; 2008. p. 321-53.
29. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol. 2010; 596: 341-58.
30. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol. 2000; 11(11): 1471-6.
31. Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer. 1993; 67(5): 1031-5.
32. Arceci RJ. Can multidrug resistance mechanisms be modified? Brit J Haematol. 2000; 110: 285-91.
33. Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res. 2005; 94: 143-96.
34. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000; 11(4): 265-83.
35. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004; 22(6): 1078-86.
36. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006; 7(7): 861-79.
37. Stupp R, Bauer J, Pagani O, Gerard B, Cerny T, Sessa C, et al. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol. 1998; 9(11): 1233-42.
38. Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol. 2000; 60(1): 83-90.
39. Fisher M, Abramov M, van Aerschot A, Xu D, Juliano RL, Herdewijn P. Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res. 2007; 35(4): 1064-74.
40. Xu D, Kang H, Fisher M, Juliano RL. Strategies for inhibition of MDR1 gene expression. Mol Pharmacol. 2004; 66(2): 268-75.
41. Jabr Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multifuntional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008; 34: 592-602.
42. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002; 54: 631-51.
43. Park JW. Liposome based drug delivery in breast cancer treatment. Breast Cancer Res. 2002; 4: 95-9.
44. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci. 2008; 7: 2586-91.
45. Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci. 2004; 93: 1993-2008.
46. Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 2006; 23: 1574-85.
47. Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm. 2007; 65(3): 300-8.
48. Wong HL, Bendayan R, Rauth AM, Wu XY. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release. 2006; 116(3): 275-84.
49. Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treatment. 2010; 119: 255-69.
50. Shuhendler AJ, O'Brien P, Rauth AM, Wu XY. On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. Drug Metabolism Drug Inter. 2008; 22(4): 201-33.
51. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973; 51(5): 1409-16.
52. Schneider E, Horton J, Yang CH, Nagagawa M, Cowan KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF-7 cell line selected for etoposide resistance. Cancer Res. 1994; 54: 152-8.
53. Volk E, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 2000; 60: 3514-21.
54. Bristow RG, Hill RP. Molecular and cellular basis of radiotherapy. Toronto: McGraw-Hill; 1998.
55. Chou TC. Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58: 621-81.
56. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27-55.
57. Chang TT, Gulati SC, Chou TC, Vega R, Gandola L, Ibrahim SM, et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. Cancer Res. 1985; 45: 2434-9.
58. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997; 57: 3375-80.